查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1654650

全球疼痛管理设备市场 - 2025 年至 2033 年

Global Pain Management Devices Market - 2025-2033
出版日期: | 出版商: DataM Intelligence | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

2024 年全球疼痛管理设备市场规模达到 38 亿美元，预计到 2033 年将达到 83 亿美元，在 2025-2033 年预测期内的复合年增长率为 9.2%。

疼痛管理设备是一种专门的医疗工具，旨在缓解慢性和急性疼痛，改善患者生活质量，减少对阿片类药物等药物治疗的依赖。这些设备采用各种技术，包括电刺激、热疗、冷冻疗法和药物传递系统，针对疼痛源头并直接或间接地缓解疼痛。

疼痛管理设备在现代医疗保健中发挥着至关重要的作用，它为传统方法可能不足或有重大风险的情况（例如鸦片类药物成瘾）提供有效的解决方案。它们使患者能够更好地控制疼痛并提高临床和家庭环境中疼痛管理的效率。

全球疼痛管理设备市场正在经历显着增长，推动因素包括慢性疼痛病症的日益普及、技术进步以及对非侵入性治疗方案的日益偏好。例如，根据美国疾病管制与预防中心 (CDC) 的数据，2021 年，估计有 20.9% 的美国成年人（5,160 万人）患有慢性疼痛，6.9%（1710 万人）患有高强度慢性疼痛，这推动了对有效疼痛管理设备的需求。

市场动态：

驱动因素与约束因素

疼痛管理设备的技术进步日新月异

疼痛管理设备的技术进步极大地推动了疼痛管理设备市场的成长，并预计在预测期内推动市场的发展。脊髓刺激和周边神经刺激等技术正变得越来越先进，可以透过精确控制刺激参数来提供有针对性的疼痛缓解。这些进步不仅可以缓解疼痛，而且透过提供更个人化的设定还可以提高患者的满意度。

例如，2023 年 1 月，雅培获得美国食品药物管理局 (FDA) 批准其 Proclaim XR 脊髓刺激 (SCS) 系统用于治疗糖尿病的一种严重併发症—疼痛性糖尿病週边神经病变 (DPN)。 Proclaim XR SCS 系统可为需要传统治疗方法（例如口服药物）替代疗法的 DPN 患者提供缓解。接受 Proclaim XR SCS 系统治疗的人还可以使用雅培的 NeuroSphere 虚拟诊所，这是一款联网护理应用程序，可让人们与医生沟通并远端接受治疗调整。

人工智慧在疼痛管理设备中的应用正在推动个人化治疗方案。这些技术即时分析患者资料，调整设备参数以达到最佳的疼痛缓解效果。例如，2024 年 9 月，Nevro Corp. 宣布美国食品药物管理局 (FDA) 批准并在有限市场上发布配备 HFX AdaptivAI 的 HFX iQ，这是脊髓刺激领域唯一的人工智慧驱动技术，是一种响应式个人化疼痛管理平台，为 HFX iQ 脊髓刺激 (SCS) 系统提供动力。

由于影像和导引系统技术的进步，微创和非侵入性手术正在成为常态。例如，2024 年 9 月，Zynex Inc. 宣布其新款 TensWave 装置已获得 FDA 批准。 TensWave 设备仅凭处方购买，它继承了 Zynex 在疼痛管理领域的强大创新传统。它采用用户友好的便携式设计，可以轻鬆融入患者的日常生活。该设备旨在透过 TENS（经皮神经电刺激）疗法有效缓解疼痛，临床证明该疗法无需药物即可减轻慢性和急性疼痛。

疼痛管理设备成本高昂

预计疼痛管理设备的高成本将在预测期内阻碍市场的成长。脊髓刺激器、神经刺激装置和输液帮浦等先进疼痛管理设备的费用对许多患者来说是难以负担的。这些设备通常需要预付款，超出了许多人的承受能力，特别是在那些此类设备保险覆盖范围有限或没有保险的国家。

例如，根据美国医生合作伙伴协会的数据，脊髓刺激器的价格根据实际情况在 7,000 美元至 10,000 美元之间。此外，波士顿科学脊髓刺激器新款售价约为 19,000 美元。

这些设备（特别是深部脑部刺激设备和程序）的成本高昂，是阻碍市场成长的重要因素，因为它限制了大量潜在患者获得治疗的机会和负担能力。这一财务障碍影响了采用率，特别是在中低收入地区，并且影响了医疗保健提供者和患者。

例如，根据美国国立卫生研究院 2024 年的数据，经通货膨胀和货币调整后的 DBS 设备平均成本为 21,496.07 美元 +- 8,944.16 美元，仅手术费用就为 14,685.22 美元 +- 8,479.66 美元，手术总费用为 4857.507, 3800 美元为 47,632.27 美元 +- 23,067.08 美元。

目录

第一章：市场介绍和范围

  • 报告目标
  • 报告范围和定义
  • 报告范围

第 2 章：高阶主管见解与关键要点

  • 市场亮点和战略要点
  • 主要趋势和未来预测
  • 按产品类型分类的片段
  • 按应用程式截取的程式码片段
  • 最终用户的程式码片段
  • 按地区分类的片段

第 3 章：动态

  • 影响因素
    • 驱动程式
      • 疼痛管理设备的技术进步日新月异
    • 限制
      • 疼痛管理设备成本高昂
    • 机会
    • 影响分析

第四章：战略洞察与产业展望

  • 市场领导者和先驱者
    • 新兴先锋和杰出参与者
    • 拥有最大销售品牌的成熟领导者
    • 拥有成熟产品的市场领导者
  • 新兴创业公司和关键创新者
  • CXO 观点
  • 最新进展与突破
  • 案例研究/正在进行的研究
  • 监管和报销情况
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲
  • 波特五力分析
  • 供应链分析
  • 专利分析
  • SWOT 分析
  • 未满足的需求和差距
  • 市场进入和扩张的推荐策略
  • 情境分析：最佳情况、基本情况和最坏情况预测
  • 定价分析和价格动态

第 5 章：疼痛管理设备市场（依产品类型）

  • 神经刺激装置
    • 脊髓刺激器
    • 週边神经刺激器
    • 深部脑部刺激器
  • 消融设备
    • 冷冻消融设备
    • 射频消融设备
  • 点滴帮浦
  • 电刺激装置

第 6 章：疼痛管理设备市场（按应用）

  • 神经性疼痛
  • 癌症疼痛
  • 肌肉骨骼疼痛
  • 偏头痛
  • 其他的

第 7 章：疼痛管理设备市场（以最终用户划分）

  • 医院
  • 专科诊所
  • 家庭护理设置
  • 物理治疗中心
  • 其他的

第 8 章：疼痛管理设备市场，按区域市场分析和成长机会

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲

第九章：竞争格局与市场定位

  • 竞争概况和主要市场参与者
  • 市占率分析与定位矩阵
  • 策略伙伴关係、併购
  • 产品组合和创新的关键发展
  • 公司基准化分析

第十章：公司简介

  • Medtronic plc
    • 公司概况
    • 产品组合和描述
    • 财务概览
    • 关键进展
    • SWOT 分析
  • Boston Scientific Corporation
  • Abbott Laboratories
  • Stryker Corporation
  • Nevro Corp
  • Aleva Neurotherapeutics
  • Zynex Inc.
  • ICU Medical, Inc.
  • inomed Medizintechnik GmbH
  • Enovis Corporation

第 11 章：假设与研究方法

  • 资料收集方法
  • 数据三角测量
  • 预测技术
  • 数据验证和确认

第 12 章：附录

简介目录
Product Code: PH8938

The global pain management devices market reached US$ 3.8 billion in 2024 and is expected to reach US$ 8.3 billion by 2033, growing at a CAGR of 9.2% during the forecast period 2025-2033.

Pain management devices are specialized medical tools designed to alleviate chronic and acute pain, improve patient quality of life, and reduce dependency on pharmacological treatments such as opioids. These devices employ various technologies, including electrical stimulation, heat therapy, cryotherapy, and drug delivery systems, to target pain at its source and provide relief either directly or indirectly.

Pain management devices play a crucial role in modern healthcare by providing effective solutions for conditions where traditional methods may be insufficient or carry significant risks, such as opioid addiction. They empower patients with better control over their pain and enhance the efficiency of pain management in clinical and home settings.

The global pain management devices market is experiencing significant growth, driven by factors such as the increasing prevalence of chronic pain conditions, technological advancements and a growing preference for non-invasive treatment options. For instance, according to the Centers for Disease Control and Prevention (CDC), in 2021, an estimated 20.9% of U.S. adults (51.6 million persons) experienced chronic pain, and 6.9% (17.1 million persons) experienced high-impact chronic pain, driving the demand for effective pain management devices.

Market Dynamics: Drivers & Restraints

Rising technological advancements in pain management devices

The rising technological advancements in pain management devices are significantly driving the growth of the Pain Management Devices market and are expected to drive the market over the forecast period. Technologies like Spinal Cord Stimulation and Peripheral Nerve Stimulation are becoming more advanced, providing targeted pain relief with precise control over stimulation parameters. These advancements not only improve pain relief but also enhance patient satisfaction by allowing more personalized settings.

For instance, in January 2023, Abbott cleared the U.S. Food and Drug Administration (FDA) approval for its Proclaim XR spinal cord stimulation (SCS) system to treat painful diabetic peripheral neuropathy (DPN), a debilitating complication of diabetes. The Proclaim XR SCS system can provide relief to DPN patients in need of alternatives to traditional treatment approaches, such as oral medication. People who receive therapy from the Proclaim XR SCS system will also be able to use Abbott's NeuroSphere Virtual Clinic, a connected care app that allows people to communicate with a physician and receive treatment adjustments remotely.

The use of AI in pain management devices is driving personalized treatment plans. These technologies analyze patient data in real time, adjusting device parameters for optimal pain relief. For instance, in September 2024, Nevro Corp. announced the U.S. Food and Drug Administration (FDA) approval and limited market release of HFX iQ with HFX AdaptivAI, the Only AI-driven technology in spinal cord stimulation, a responsive, personalized pain management platform powering the HFX iQ spinal cord stimulation (SCS) system.

Minimally invasive and non-invasive procedures are becoming the norm due to technological advancements in imaging and guidance systems. For instance, in September 2024, Zynex Inc. announced FDA clearance of its new TensWave device. The TensWave device, by prescription only, builds on Zynex's strong legacy of innovation in pain management. It offers a user-friendly, portable design that can be easily integrated into patients' daily routines. The device aims to provide effective pain relief through TENS (Transcutaneous Electrical Nerve Stimulation) therapy, which has been clinically proven to reduce chronic and acute pain without needing medication.

High cost of pain management devices

The high cost of pain management devices is expected to hamper the growth of the market over the forecast period. The cost of advanced pain management devices such as spinal cord stimulators, neurostimulation devices, and infusion pumps can be prohibitive for many patients. These devices often require upfront payments that are beyond the reach of many individuals, especially in countries where insurance coverage for such devices is limited or nonexistent.

For instance, according to the Physician Partners of America, the price for a spinal cord stimulator ranges from $7,000-$10,000 depending on the practice. Additionally, a Boston Scientific Spinal Cord Stimulator costs around $19,000 for newer models.

The high cost of these devices especially fro deep brain stimulation devices and procedures is a significant factor that hampers market growth by limiting access and affordability for a large segment of potential patients. This financial barrier affects adoption rates, particularly in low- and middle-income regions and impacts both healthcare providers and patients.

For instance, according to the National Institute of Health, 2024, the inflation and currency-adjusted mean cost of the DBS device was USD 21,496.07 +- USD 8,944.16, the cost of surgery alone was USD 14,685.22 +- USD 8,479.66, the total cost of surgery was USD 40,942.85 +- USD 17,987.43 and the total cost of treatment until 1 year of follow-up was USD 47,632.27 +- USD 23,067.08.

Segment Analysis

The global pain management devices market is segmented based on product type, application, end-user and region.

Product Type:

The neurostimulation devices segment is expected to dominate the pain management devices market share

Neurostimulation devices, such as Spinal Cord Stimulation (SCS) and Deep Brain Stimulation (DBS), are highly effective in managing chronic pain by targeting specific pain pathways. This targeted approach allows for customized treatment settings that adapt to the patient's specific pain pattern.

For instance, in January 2024, Abbott received approval from the U.S. Food and Drug Administration (FDA) to launch the Liberta RC DBS system, the world's smallest rechargeable deep brain stimulation (DBS) device with remote programming. The Liberta RC DBS system requires the fewest recharges of any FDA-approved DBS system, needing only 10 recharge sessions a year for most people.

Neurostimulation devices are used to treat a broad spectrum of chronic pain conditions, including neuropathic pain, back pain, post-surgical pain, and migraine. For instance, in February 2024, Boston Scientific Corporation cleared U.S. Food and Drug Administration (FDA) approval for an expanded indication of the WaveWriter SCS Systems for the treatment of chronic low back and leg pain in people without prior back surgery, commonly referred to as non-surgical back pain (NSBP). The versatility of neurostimulation devices contributes to their dominance in the market as they cater to multiple patient needs with different pain profiles.

Advances in neurostimulation technology, such as minimally invasive implantation techniques, have made these devices more accessible and less intimidating for patients. The devices with a wearable approach that can be adjusted via smartphone, make it user-friendly and more acceptable to patients who may otherwise be resistant to invasive surgery.

For instance, in April 2023, Neuspera Medical, a medical device company developing implantable devices for patients battling chronic illnesses, announced that it received U.S. Food and Drug Administration (FDA) clearance for the next-generation Neuspera ultra-miniaturized system. The system is comprised of a micro-implant that delivers neurostimulation therapy through a wireless platform including a wearable transmitter and iPad-based clinician programmer.

Geographical Analysis

North America is expected to hold a significant position in the pain management devices market share

North America especially the United States is home to several major players in the pain management devices market, including Medtronic, Stryker Corporation, Boston Scientific, Abbott and other emerging players. These companies have extensive R&D operations in the region, focusing on the development of advanced pain management solutions, resulting in innovations, which integrate advancements for personalized pain management.

For instance, in April 2024, Medtronic plc announced that the U.S. Food and Drug Administration (FDA) has approved the Inceptiv closed-loop rechargeable spinal cord stimulator (SCS) for the treatment of chronic pain. Inceptiv is the first Medtronic SCS device to offer a closed-loop feature that senses biological signals along the spinal cord and automatically adjusts stimulation in real-time, keeping therapy in harmony with the motions of daily life.

Additionally, in July 2024, Stryker launched the MultiGen 2 Radiofrequency (RF) Generator, this technology provides physicians with the efficiency, control and reliability they need when performing RF ablation, a minimally invasive procedure that can provide lasting relief to those suffering from facet joint pain. MultiGen 2 is the next generation of radiofrequency ablation that provides physicians with control and customization to perform chronic pain management procedures with confidence.

The U.S. FDA's rigorous but predictable approval process makes North America an ideal market for new pain management devices. Companies like Abbott and Boston Scientific frequently conduct pivotal clinical trials in North America to gain regulatory approval for new products. This gives North American patients early access to innovative pain relief technologies, fostering market leadership.

Asia-Pacific is growing at the fastest pace in the pain management devices market

Asia-Pacific is increasingly adapting global pain management technologies to local needs, leading to rapid market growth. For instance, the Abbott Proclaim XR system has been adapted for use in countries like India and China with specific features tailored to the local healthcare landscape. This device offers both spinal cord stimulation and peripheral nerve stimulation, making it suitable for a wide range of chronic pain conditions prevalent in the region.

The major market players and emerging players in the region developing advanced smart devices for pain management. For instance, in September 2022, UltrcareCare Pro introduced TENS 2.0, a Smart - Wearable, Wireless and Pocket-sized Pain Management Device for joint, muscular and everyday pain featuring a modern design that is truly wireless with the size of a smartwatch.

Increasing awareness of chronic pain and available treatments is driving market growth in APAC. Government and non-governmental organizations are conducting awareness campaigns about the benefits of pain management devices. For instance, in Australia, initiatives by Pain Australia have highlighted the benefits of devices like spinal cord stimulators and how they can improve the quality of life for chronic pain patients. These programs are educating both healthcare providers and patients, leading to higher adoption rates of pain management devices.

Competitive Landscape

The major global players in the pain management devices market include Medtronic plc, Boston Scientific Corporation, Abbott Laboratories, Stryker Corporation, Nevro Corp, Aleva Neurotherapeutics, Zynex Inc., ICU Medical, Inc., inomed Medizintechnik GmbH, Enovis Corporation and among others.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global pain management devices market report delivers a detailed analysis with 62 key tables, more than 57 visually impactful figures, and 187 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Product Type
  • 2.4. Snippet by Application
  • 2.5. Snippet by End-User
  • 2.6. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Rising Technological Advancements in Pain Management Devices
    • 3.1.2. Restraints
      • 3.1.2.1. High Cost of Pain Management Devices
    • 3.1.3. Opportunity
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with largest selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. Emerging Startups and Key Innovators
  • 4.3. CXO Perspectives
  • 4.4. Latest Developments and Breakthroughs
  • 4.5. Case Studies/Ongoing Research
  • 4.6. Regulatory and Reimbursement Landscape
    • 4.6.1. North America
    • 4.6.2. Europe
    • 4.6.3. Asia Pacific
    • 4.6.4. Latin America
    • 4.6.5. Middle East & Africa
  • 4.7. Porter's Five Force Analysis
  • 4.8. Supply Chain Analysis
  • 4.9. Patent Analysis
  • 4.10. SWOT Analysis
  • 4.11. Unmet Needs and Gaps
  • 4.12. Recommended Strategies for Market Entry and Expansion
  • 4.13. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.14. Pricing Analysis and Price Dynamics

5. Pain Management Devices Market, By Product Type

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 5.1.2. Market Attractiveness Index, By Product Type
  • 5.2. Neurostimulation Devices*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 5.2.3. Spinal Cord Stimulators
    • 5.2.4. Peripheral Nerve Stimulators
    • 5.2.5. Deep Brain Stimulators
  • 5.3. Ablation Devices
    • 5.3.1. Cryoablation Devices
    • 5.3.2. Radiofrequency Ablation Devices
  • 5.4. Infusion Pumps
  • 5.5. Electrical Stimulation Devices

6. Pain Management Devices Market, By Application

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 6.1.2. Market Attractiveness Index, By Application
  • 6.2. Neuropathic Pain*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Cancer Pain
  • 6.4. Musculoskeletal Pain
  • 6.5. Migraine Pain
  • 6.6. Others

7. Pain Management Devices Market, By End-User

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 7.1.2. Market Attractiveness Index, By End-User
  • 7.2. Hospitals*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Specialty Clinics
  • 7.4. Homecare Settings
  • 7.5. Physiotherapy Centers
  • 7.6. Others

8. Pain Management Devices Market, By Regional Market Analysis and Growth Opportunities

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 8.1.2. Market Attractiveness Index, By Region
  • 8.2. North America
    • 8.2.1. Introduction
    • 8.2.2. Key Region-Specific Dynamics
    • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.2.7. U.S.
    • 8.2.8. Canada
    • 8.2.9. Mexico
  • 8.3. Europe
    • 8.3.1. Introduction
    • 8.3.2. Key Region-Specific Dynamics
    • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.3.7. Germany
    • 8.3.8. U.K.
    • 8.3.9. France
    • 8.3.10. Spain
    • 8.3.11. Italy
    • 8.3.12. Rest of Europe
  • 8.4. South America
    • 8.4.1. Introduction
    • 8.4.2. Key Region-Specific Dynamics
    • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.4.7. Brazil
    • 8.4.8. Argentina
    • 8.4.9. Rest of South America
  • 8.5. Asia-Pacific
    • 8.5.1. Introduction
    • 8.5.2. Key Region-Specific Dynamics
    • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.5.7. China
    • 8.5.8. India
    • 8.5.9. Japan
    • 8.5.10. South Korea
    • 8.5.11. Rest of Asia-Pacific
  • 8.6. Middle East and Africa
    • 8.6.1. Introduction
    • 8.6.2. Key Region-Specific Dynamics
    • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9. Competitive Landscape and Market Positioning

  • 9.1. Competitive Overview and Key Market Players
  • 9.2. Market Share Analysis and Positioning Matrix
  • 9.3. Strategic Partnerships, Mergers & Acquisitions
  • 9.4. Key Developments in Product Portfolios and Innovations
  • 9.5. Company Benchmarking

10. Company Profiles

  • 10.1. Medtronic plc*
    • 10.1.1. Company Overview
    • 10.1.2. Product Portfolio and Description
    • 10.1.3. Financial Overview
    • 10.1.4. Key Developments
    • 10.1.5. SWOT Analysis
  • 10.2. Boston Scientific Corporation
  • 10.3. Abbott Laboratories
  • 10.4. Stryker Corporation
  • 10.5. Nevro Corp
  • 10.6. Aleva Neurotherapeutics
  • 10.7. Zynex Inc.
  • 10.8. ICU Medical, Inc.
  • 10.9. inomed Medizintechnik GmbH
  • 10.10. Enovis Corporation

LIST NOT EXHAUSTIVE

11. Assumption and Research Methodology

  • 11.1. Data Collection Methods
  • 11.2. Data Triangulation
  • 11.3. Forecasting Techniques
  • 11.4. Data Verification and Validation

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us